Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
COVID-19 may cause severe pneumonitis that require ventilatory support in some patients, the
ICU mortality is as high as 62%. Hospitals do not have enough ICU beds to handle the demand
and to date there is no effective cure.
We explore a treatment administered in a randomized clinical trial that could prevent ICU
admission and reduce mortality.
The overall hypothesis to be evaluated is that HBO reduce mortality, increase hypoxia
tolerance and prevent organ failure in patients with COVID19 pneumonitis by attenuating the
inflammatory response.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Karolinska Institutet Karolinska University Hospital
Collaborators:
Blekinge County Council Hospital JK Biostatistics AB Karolinska Institutet Karolinska Trial Alliance The Swedish Research Council University of California, San Diego University of Regensburg